Patents by Inventor Kathleen Boyles

Kathleen Boyles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11913023
    Abstract: The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: February 27, 2024
    Assignee: Walking Fish Therapeutics, Inc.
    Inventors: Kathleen Boyle, Hangil Park, Srinivas Kothakota, Mark Selby, Thomas Brennan, Lewis T. Williams
  • Publication number: 20240034995
    Abstract: The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.
    Type: Application
    Filed: May 11, 2023
    Publication date: February 1, 2024
    Applicant: Walking Fish Therapeutics
    Inventors: Kathleen Boyle, Hangil Park, Srinivas Kothakota, Mark Selby, Thomas Brennan, Lewis T. Williams
  • Publication number: 20240002793
    Abstract: The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell”), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.
    Type: Application
    Filed: May 9, 2023
    Publication date: January 4, 2024
    Applicant: Walking Fish Therapeutics
    Inventors: Kathleen Boyle, Hangil Park, Srinivas Kothakota, Mark Selby, Thomas Brennan, Lewis T. Williams
  • Publication number: 20230137343
    Abstract: The present invention relates to methods and combination therapies for enhancing the activity and function of non-B cell immune cells (such as T cells) using genetically modified B cells. These methods and combinations can be used, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like.
    Type: Application
    Filed: October 6, 2022
    Publication date: May 4, 2023
    Inventors: Kathleen BOYLE, Hangil PARK, Srinivas KOTHAKOTA, Mark SELBY, Thomas BRENNAN, Lewis T. WILLIAMS, Rosa Romano, Weijie Lan
  • Publication number: 20220324835
    Abstract: Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.
    Type: Application
    Filed: January 25, 2019
    Publication date: October 13, 2022
    Inventors: Paul A. BARSANTI, Neil F. BENCE, Jennifa GOSLING, Anjanabha SAHA, Asad M TAHERBHOY, Christoph W. ZAPF, Kathleen BOYLE, Mario CARDOZO, Jeffrey MIHALIC, Morgan LAWRENZ, Mark GALLOP, Jilliane BRUFFEY, Thomas CUMMINS, Daniel ROBBINS, Hiroko TANAKA, Chenbo WANG, Frederick COHEN, Wylie PALMER, Arthur T. SANDS, Hunter SHUNATONA
  • Publication number: 20220073876
    Abstract: The present invention relates to genetically modified B cells and their uses thereof, for example, for the treatment of a variety of diseases and disorders, including cancer, heart disease, inflammatory disease, muscle wasting disease, neurological disease, and the like. In certain embodiments, the invention relates to an isolated modified B cell (“CAR-B cell), capable of expressing a chimeric receptor (“CAR-B receptor”), wherein said chimeric receptor comprises (a) an extracellular domain; (b) a transmembrane domain; and (c) a cytoplasmic domain that comprises at least one signaling domain. In various embodiments, the invention comprises an isolated modified B cell, wherein said B cell is capable of expressing and secreting a payload, wherein the payload is not naturally expressed in a B cell or is expressed at higher levels than is naturally expressed in a B cell. In various embodiments, the payload is an antibody or fragment thereof.
    Type: Application
    Filed: September 2, 2021
    Publication date: March 10, 2022
    Inventors: Kathleen Boyle, Hangil Park, Srinivas Kothakota, Mark Selby, Thomas Brennan, Lewis T. Williams
  • Publication number: 20100183620
    Abstract: The invention encompasses methods and compositions for increasing or decreasing collagen 1A1 expression and/or ?-smooth muscle actin expression in lung fibroblasts using SERPINE2 and antagonists of SERPINE2. The invention also encompasses methods and compositions for increasing or decreasing the formation of myofibroblasts. The invention further provides methods and compositions for treatment of lung diseases, such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.
    Type: Application
    Filed: November 25, 2009
    Publication date: July 22, 2010
    Inventors: KAUMUDI BHAWE, Elizabeth Bosch, Kathleen Boyle, Arthur Brace, Anuk Das, Francis Farrell, Pitchumani Sivakumar, Jeffrey Finer, Kristen Pierce, Kathleen M. Sullivan, Brian Wong
  • Publication number: 20070131573
    Abstract: Certain embodiments can comprise an apparatus, comprising a non-garment container for a device. The container can comprise: a first portion; a second portion couplable to the first portion; and a releasable closure attached to the first portion and the second portion for closing a releasably closable first opening adjacent the first portion and said second portion. The container can define a second opening opposing the first opening. The first opening can close to form a plurality of sub-openings.
    Type: Application
    Filed: September 10, 2004
    Publication date: June 14, 2007
    Inventor: Kathleen Boyles
  • Patent number: 6991243
    Abstract: A lightweight collapsible four-wheeled scooter with a large platform, the scooter including a height-adjustable non-steering foldable handle assembly in front for gripping by a rider, an adjustable height removable push bar extending to the rear for use by a pusher, a pair of non-swivelable wheels extending to the rear, and a pair of swivelable wheels in the front to enable steering, the scooter being capable of supporting a single standing rider or multiple standing riders, the scooter platform being capable of accommodating an optional removable seat having an optional removable carry basket.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: January 31, 2006
    Inventors: Manus J. Boyle, Kathleen A. Boyle
  • Publication number: 20050057012
    Abstract: A lightweight collapsible four-wheeled scooter with a large platform, the scooter including a height-adjustable non-steering foldable handle assembly in front for gripping by a rider, an adjustable height removable push bar extending to the rear for use by a pusher, a pair of non-swivelable wheels extending to the rear, and a pair of swivelable wheels in the front to enable steering, the scooter being capable of supporting a single standing rider or multiple standing riders, the scooter platform being capable of accommodating an optional removable seat having an optional removable carry basket.
    Type: Application
    Filed: September 12, 2003
    Publication date: March 17, 2005
    Inventors: Manus Boyle, Kathleen Boyle